AU2001293858A1 - Immunomodulatory protein derived from the yaba monkey tumor virus - Google Patents

Immunomodulatory protein derived from the yaba monkey tumor virus

Info

Publication number
AU2001293858A1
AU2001293858A1 AU2001293858A AU9385801A AU2001293858A1 AU 2001293858 A1 AU2001293858 A1 AU 2001293858A1 AU 2001293858 A AU2001293858 A AU 2001293858A AU 9385801 A AU9385801 A AU 9385801A AU 2001293858 A1 AU2001293858 A1 AU 2001293858A1
Authority
AU
Australia
Prior art keywords
disclosed
protein derived
tumor virus
immunomodulatory protein
genes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001293858A
Inventor
Dalia Cohen
Uwe Jochen Dengler
Alyce Lynn Finelli
Felix Freuler
Mary Konsolaki
Mischa Werner Henri Marie Reinhardt
Susan Zusman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of AU2001293858A1 publication Critical patent/AU2001293858A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New breeds of animals
    • A01K67/033—Rearing or breeding invertebrates; New breeds of invertebrates
    • A01K67/0333—Genetically modified invertebrates, e.g. transgenic, polyploid
    • A01K67/0337—Genetically modified Arthropods
    • A01K67/0339—Genetically modified insects, e.g. Drosophila melanogaster, medfly
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

Transgenic flies displaying altered phenotypes due to expression of the Abeta and C 99 portions of the human APP gene are disclosed. Use of these flies in a method to identify Drosophila genes and the human homologs of these Drosophila genes, that are potentially involved in Alzheimer's Disease, is also disclosed. The use of said human homologs as drug targets for the development of therapeutics to treat Alzheimer's Disease and other conditions associated with defects in the APP pathway, as well as pharmaceutical compositions comprising substances directed to these genes, are also disclosed.
AU2001293858A 2000-09-29 2001-10-01 Immunomodulatory protein derived from the yaba monkey tumor virus Abandoned AU2001293858A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23689300P 2000-09-29 2000-09-29
US60/236,893 2000-09-29
US29830901P 2001-06-14 2001-06-14
US60/298,309 2001-06-14
PCT/EP2001/011345 WO2002026820A2 (en) 2000-09-29 2001-10-01 Immunomodulatory protein derived from the yaba monkey tumor virus

Publications (1)

Publication Number Publication Date
AU2001293858A1 true AU2001293858A1 (en) 2002-04-08

Family

ID=26930201

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001293858A Abandoned AU2001293858A1 (en) 2000-09-29 2001-10-01 Immunomodulatory protein derived from the yaba monkey tumor virus

Country Status (11)

Country Link
US (2) US6900367B2 (en)
EP (1) EP1324652B1 (en)
JP (1) JP2004509646A (en)
KR (1) KR20030051664A (en)
AT (1) ATE359704T1 (en)
AU (1) AU2001293858A1 (en)
CA (1) CA2423613A1 (en)
DE (1) DE60127982T2 (en)
ES (1) ES2284697T3 (en)
PT (1) PT1324652E (en)
WO (1) WO2002026820A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7761605B1 (en) * 2001-12-20 2010-07-20 Mcafee, Inc. Embedded anti-virus scanner for a network adapter
US20040194158A1 (en) * 2003-03-28 2004-09-30 Baylor College Of Medicine Model for neurodegenerative disorders
US7847146B2 (en) * 2003-03-28 2010-12-07 Baylor College Of Medicine Model for neurodegenerative disorders
CA2543058A1 (en) * 2003-10-20 2005-05-12 Envivo Pharmaceuticals, Inc. Transgenic flies expressing mutant a.beta.42
US20090016963A1 (en) * 2003-10-22 2009-01-15 Dalia Cohen Genes involved in neurodegenerative conditions
WO2005098433A2 (en) * 2004-04-01 2005-10-20 Novartis Ag Diagnostic assays for alzheimer’s disease
WO2005112978A2 (en) * 2004-05-21 2005-12-01 University Of Utah Research Foundation Methods and compositions related to delivery of chemical compounds to invertebrate embryos
EP1859274A2 (en) * 2005-03-07 2007-11-28 Novartis AG Genes involved in neurodegenerative conditions
KR100816797B1 (en) * 2006-05-30 2008-03-26 건국대학교 산학협력단 Drosophila CG5116 gene mutant generating black maculation in a period of larva and preparation method thereof
AU2007261584A1 (en) * 2006-06-16 2007-12-27 Envivo Pharmaceutical Inc. Transgenic flies expressing tau and amyloid precursor fragment
JP2011501652A (en) * 2007-09-12 2011-01-13 プロビオドルグ エージー Transgenic mouse
US10660318B2 (en) 2013-08-20 2020-05-26 Tosk, Inc. Non-mammalian RAS transgenic animal model
CN108707628B (en) * 2018-05-28 2021-11-23 上海海洋大学 Preparation method of zebra fish notch2 gene mutant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014200A1 (en) 1992-01-07 1993-07-22 Tsi Corporation Transgenic animal models for alzheimer's disease
US5851787A (en) 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US5455169A (en) 1992-06-04 1995-10-03 Alzheimer's Institute Of America, Inc. Nucleic acids for diagnosing and modeling Alzheimer's disease
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6278039B1 (en) 1997-05-28 2001-08-21 Axys Pharmaceuticals, Inc. C. elegans deletion mutants
US6489535B1 (en) * 1999-03-18 2002-12-03 The Board Of Trustees Of The Leland Stanford Junior University Non-mammalian transgenic animal having an adult onset neurodegenerative phenotype
US7125687B1 (en) 2000-05-05 2006-10-24 Exelixis, Inc. Presenilin enhancers assays

Also Published As

Publication number Publication date
ES2284697T3 (en) 2007-11-16
WO2002026820A3 (en) 2002-10-10
DE60127982D1 (en) 2007-05-31
EP1324652A2 (en) 2003-07-09
JP2004509646A (en) 2004-04-02
DE60127982T2 (en) 2008-01-17
CA2423613A1 (en) 2002-04-04
US6900367B2 (en) 2005-05-31
US20050138676A1 (en) 2005-06-23
PT1324652E (en) 2007-07-23
KR20030051664A (en) 2003-06-25
EP1324652B1 (en) 2007-04-18
WO2002026820A2 (en) 2002-04-04
ATE359704T1 (en) 2007-05-15
US20020174446A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
AU2001293858A1 (en) Immunomodulatory protein derived from the yaba monkey tumor virus
Menzies et al. Puromycin-sensitive aminopeptidase protects against aggregation-prone proteins via autophagy
MX2009005279A (en) N- (methyl) -1h- pyrazol- 3 -amine, n- (methyl) -pyridin-2-amine and n- (methyl) -thiaz0l-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's.
HUP0302114A2 (en) Liquis pharmaceutical composition comprising erythropoietin protein, method for its preparation and its use
MXPA02012164A (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
SI1427708T1 (en) Amino-phthalazinone derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
ATE400573T1 (en) 1H-IMIDAZOCINOLINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
ATE409176T1 (en) 1-PHENYLALKANECARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
WO2005065195A3 (en) Phenylamide and pyridylamide beta-secretase inhibitors for the treatment of alzheimer's disease
ATE557015T1 (en) 3,4-DIARYLPYRAZOLES AS PROTEIN KINASE INHIBITORS
MY142019A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BR0212841A (en) Active aminoindazole derivative as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
ECSP10010265A (en) PHARMACEUTICALLY ACCEPTABLE SALTS OF (3 - {[[3- (6-AMINO-2-BUTOXI-8-OXO-7,8 DIHIDRO-9H-PURIN-9-IL) PROPIL] (3-MORFOLIN-4 ILPROPIL) AMINO] METHYL} PHENYL)
Tahir et al. Retinoic acid induced-1 (Rai1) regulates craniofacial and brain development in Xenopus
Xu et al. MicroRNA-27b inhibition promotes Nrf2/ARE pathway activation and alleviates intracerebral hemorrhage-induced brain injury
MXPA05009719A (en) Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
ATE396986T1 (en) PYRIMIDYLPYRROLE DERIVATIVES THAT ACTION AS KINASE INHIBITORS
Noreen et al. New insights into the spread of resistance to artemisinin and its analogues
DE60221283D1 (en) USE OF OXINDOLE DERIVATIVES FOR TREATING DISEASES RELATED TO DEMENTIA, ALZHEIMER'S DISEASE AND AIDS ASSOCIATED WITH GLYCOGENSYNTHASEKINASE-3
CN101489542B (en) Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases
NO20070665L (en) Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases
WO2002046767A3 (en) Diagnosis and treatment of alzheimer's disease
Cho et al. Anti-varicella zoster virus and related anti-inflammation effects of ethanolic extract of Elaeocarpus sylvestris
AU2002333536A1 (en) Carboxylate-gated-nitroxide (cgn) compounds and compositions and methods of use thereof
HUP0400737A2 (en) Use of l-carnitine for preparation of compositions for stabilizing the proteins